Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Gain Therapeutics Inc (GANX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: GANX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.05% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 58.99M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 7 | Beta 0.11 | 52 Weeks Range 0.89 - 3.19 | Updated Date 06/30/2025 |
52 Weeks Range 0.89 - 3.19 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.83 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -97.1% | Return on Equity (TTM) -290.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49930746 | Price to Sales(TTM) 255.5 |
Enterprise Value 49930746 | Price to Sales(TTM) 255.5 | ||
Enterprise Value to Revenue 138.33 | Enterprise Value to EBITDA -1.55 | Shares Outstanding 29945600 | Shares Floating 28219270 |
Shares Outstanding 29945600 | Shares Floating 28219270 | ||
Percent Insiders 4.42 | Percent Institutions 9.53 |
Analyst Ratings
Rating 3 | Target Price 8 | Buy 4 | Strong Buy 3 |
Buy 4 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Gain Therapeutics Inc
Company Overview
History and Background
Gain Therapeutics, Inc. was founded in 2017. It is a clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases and other serious conditions characterized by impaired protein folding and trafficking.
Core Business Areas
- Small Molecule Drug Development: Focuses on identifying and developing small molecule therapeutics to address misfolded proteins and improve cellular function. Their platform, Structurally Targeted Allosteric Regulators (STARs), targets protein misfolding.
Leadership and Structure
Gain Therapeutics is led by a management team with experience in drug development and biotechnology. Their organizational structure is typical of a clinical-stage biotech company.
Top Products and Market Share
Key Offerings
- GT-02287: A brain-penetrant structurally targeted allosteric regulator (STAR) that targets GCase, an enzyme involved in Gaucher disease and Parkinson's disease. Currently in Phase 1 clinical trials. Competitors in Parkinson's include Denali Therapeutics (DNLI) and Prevail Therapeutics (acquired by Eli Lilly).
- GT-02329: A STAR molecule targeting as a potential treatment for neurodegenerative diseases related to LAMP2A, another protein misfolding target. Still in preclinical development. Competitors are less defined at this stage as it is still preclinical.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high risk, high reward, and long development timelines. It's driven by innovation in drug discovery and development.
Positioning
Gain Therapeutics is positioned as a company developing novel therapies targeting protein misfolding in neurodegenerative diseases, a significant unmet medical need. Its competitive advantage lies in its STARs platform.
Total Addressable Market (TAM)
The neurodegenerative disease market is substantial and growing, projected to reach hundreds of billions of dollars. Gain Therapeutics is addressing a segment of this market related to protein misfolding. The exact TAM varies depending on the specific disease targeted and competitive landscape.
Upturn SWOT Analysis
Strengths
- Novel STARs platform
- Targeting unmet medical needs
- Experienced management team
- Focus on validated drug targets
Weaknesses
- Early-stage clinical development
- High cash burn rate
- Reliance on successful clinical trials
- Limited product portfolio
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of STARs platform to new disease areas
- Positive clinical trial results
- Growing market for neurodegenerative disease therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Funding challenges
Competitors and Market Share
Key Competitors
- DEN (Denali Therapeutics Inc.)
- LLY (Eli Lilly and Company)
Competitive Landscape
Gain Therapeutics is a small company competing with much larger, established pharmaceutical companies. Its advantage lies in its novel platform, but it faces significant challenges in funding and clinical development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as this is a early clinical stage company.
Future Projections: Future growth is dependent on the clinical trial results and partnerships. Analyst projections are not available.
Recent Initiatives: Focus on advancing GT-02287 through Phase 1 clinical trials and progressing preclinical programs targeting LAMP2A.
Summary
Gain Therapeutics is an early-stage biotech company focused on novel therapies for neurodegenerative diseases. Their STARs platform holds promise, but the company faces significant risks inherent in drug development. Successful clinical trials and strategic partnerships are crucial for their future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in biotechnology companies is highly speculative and carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gain Therapeutics Inc
Exchange NASDAQ | Headquaters Bethesda, MD, United States | ||
IPO Launch date 2021-03-18 | President, CEO & Director Mr. Gene Mack M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 23 | Website https://gaintherapeutics.com |
Full time employees 23 | Website https://gaintherapeutics.com | ||
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.